Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: idos who wrote (752)	7/1/2008 3:58:24 PM
From: tuck	Respond to of 804

Wow, gotta say I'm a bit surprised, and if MOGN hadn't been taken out, I might have been hurt. Bit of buyer's remorse for Eisai, along with Lundbeck. Cheers, Tuck

To: idos who wrote (752)	12/3/2008 8:02:56 AM
From: idos	Respond to of 804

Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes biz.yahoo.com Randomized Comparator Study to Evaluate Efficacy of Commercially Available Hypomethylating Agents WOODCLIFF LAKE, N.J., Dec. 2 /PRNewswire/ -- Eisai Corporation of North America today announced that it plans to initiate the first clinical trial evaluating the activity of Dacogen® (decitabine for injection) compared to Vidaza® (azacitidine) in adult patients with intermediate-1, intermediate-2 or high-risk myelodysplastic syndromes (MDS), a potentially life-threatening group of bone marrow diseases that limit the production of functional blood cells. The head-to-head trial will be conducted in the United States and will directly compare Dacogen® to Vidaza® with a primary endpoint of complete response rate (including marrow complete response). "Previous to the introduction of the hypomethylating agents, supportive care was the only treatment option for patients living with MDS," said Dr. Hagop M. Kantarjian, chairman of the Leukemia Department and professor of medicine, University of Texas M.D. Anderson Cancer Center. "This study, for the first time, will provide physicians with important information to understand how these two agents compare when treating patients with MDS, who currently have a generally poor prognosis, with life expectancies shorter than those with lung cancer." Study Design This randomized, multi-center, open-label study will be conducted among 228 adult patients with intermediate-1, intermediate-2 and high-risk MDS. Patients will be randomized on a 1:1 ratio to either Dacogen® or Vidaza®. Each treatment arm will be stratified by IPSS risk group and type of MDS (primary vs. secondary). The study's primary objective is to compare the complete response rates, including bone marrow response rates, for Dacogen® versus Vidaza®. "Findings from this trial could help clarify the fundamental differences between Dacogen and Vidaza and ultimately help clinicians with treatment selection," said Dr. Anastasios Raptis, co-director, Myelodysplastic Syndrome Program, attending, Stem Cell Transplant Program and clinical assistant professor of medicine, University of Pittsburgh School of Medicine. "This study takes into account recent data that suggest that treatment of patients should continue for as long as they receive clinical benefit or until their disease progresses."